BJS Academy>Randomized clinical ...>21 Gene assay to inf...
21-Gene assay to inform chemotherapy benefit in node-positive breast cancer.
1 January 2022
Randomized clinical trials Breast
Related articles
Aspirin vs placebo as adjuvant therapy for breast cancer. The Alliance A011502 randomized trial.
Chen WY, Ballman KV, Partridge AH, Hahn OM, Briccetti FM
JAMA 2024; 331: 1714-1721.
Some 3020 women with non-metastatic breast cancer were enrolled. The study was terminated after the first interim analysis for futility. 300mg aspirin per day for a median of 33.8 months did not improve breast cancer recurrence (hazard ratio 1.27, 95 per cent confidence interval 0.99 to 1.63, P=0.06) or survival (1.19, 0.82 to 1.72).
Comment: Theoretical advantage not proven.
Event-free survival with pembrolizumab in early triple-negative breast cancer.
N Engl J Med 2022; 386: 556-567.
Use of neoadjuvant pembrolizumab plus chemotherapy, with additional pembrolizumab postoperatively improved event-free survival from 76.8 to 84.5 per cent at 36 months in this study that included 1174 women.
Comment: New standard of care?
Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG).
Lancet Oncol 2022; 23: 382-392.
Aromatase inhibitors were compared with tamoxifen in premenopausal women with ovarian suppression in a study that included 7030 patients followed for a median of eight years. Aromatase inhibitors reduce recurrence, especially in years 1 to 4 (13.2 per cent absolute risk reduction). Recurrence rates were similar in years 5 to 9. Mortality rates were also similar.
Comment: Initial treatment with aromatase inhibitors in this group seems optimal.
Copied!